Fig. 2From: Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctiona. Trametinib concentration-time by hepatic dysfunction group (dose standardized to 2 mg) (n = 22). (A) Individual concentration (B) Mean concentration. b. Unbound trametinib fractions (n = 24). (A) by liver function group and time (B) Linear Regression of Unbound Trametinib Fraction vs. Serum Albumin for Protein Binding Analysis Population (p = 0.26)Back to article page